These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28666965)

  • 1. Individualizing duration of antibiotic therapy in community-acquired pneumonia.
    Aliberti S; Ramirez J; Giuliani F; Wiemken T; Sotgiu G; Tedeschi S; Carugati M; Valenti V; Marchioni M; Camera M; Piro R; Del Forno M; Milani G; Faverio P; Richeldi L; Deotto M; Villani M; Voza A; Tobaldini E; Bernardi M; Bellone A; Bassetti M; Blasi F
    Pulm Pharmacol Ther; 2017 Aug; 45():191-201. PubMed ID: 28666965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.
    Uranga A; España PP; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; Tomás L; Camino J; Nuñez J; Capelastegui A
    JAMA Intern Med; 2016 Sep; 176(9):1257-65. PubMed ID: 27455166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia.
    Uranga A; Artaraz A; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; García JA; Camino J; España PP
    BMC Pulm Med; 2020 Oct; 20(1):261. PubMed ID: 33028293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
    Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
    Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia.
    Lee RW; Lindstrom ST
    Respirology; 2007 Jan; 12(1):111-6. PubMed ID: 17207035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia.
    Simonetti A; Viasus D; Garcia-Vidal C; Adamuz J; Roset A; Manresa F; Dorca J; Gudiol F; Carratalà J
    Clin Microbiol Infect; 2012 Nov; 18(11):1149-55. PubMed ID: 22115052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.
    Blum CA; Nigro N; Winzeler B; Suter-Widmer I; Schuetz P; Briel M; Bingisser R; Zimmerli W; Ullmer E; Elsaesser H; Tarr P; Wirz S; Thomann R; Hofmann E; Rodondi N; Duplain H; Burki D; Mueller B; Christ-Crain M
    Trials; 2014 Jun; 15():257. PubMed ID: 24974155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia--a propensity-adjusted analysis.
    Choudhury G; Mandal P; Singanayagam A; Akram AR; Chalmers JD; Hill AT
    Clin Microbiol Infect; 2011 Dec; 17(12):1852-8. PubMed ID: 21919994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study.
    Vaughn VM; Flanders SA; Snyder A; Conlon A; Rogers MAM; Malani AN; McLaughlin E; Bloemers S; Srinivasan A; Nagel J; Kaatz S; Osterholzer D; Thyagarajan R; Hsaiky L; Chopra V; Gandhi TN
    Ann Intern Med; 2019 Aug; 171(3):153-163. PubMed ID: 31284301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in clinical and economic outcomes with empiric antibiotic therapy covering atypical pathogens for community-acquired pneumonia patients: a multicenter cohort study.
    Ye X; Ma J; Hu B; Gao X; He L; Shen W; Weng L; Cai L; Huang Y; Hu Z; Xu J; Zhao L; Huang M; Cui X; Tu C
    Int J Infect Dis; 2015 Nov; 40():102-7. PubMed ID: 25813554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.
    Christ-Crain M; Stolz D; Bingisser R; Müller C; Miedinger D; Huber PR; Zimmerli W; Harbarth S; Tamm M; Müller B
    Am J Respir Crit Care Med; 2006 Jul; 174(1):84-93. PubMed ID: 16603606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
    Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
    Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to first antibiotic dose for patients hospitalised with community-acquired pneumonia.
    Yahav D; Leibovici L; Goldberg E; Bishara J; Paul M
    Int J Antimicrob Agents; 2013 May; 41(5):410-3. PubMed ID: 23453615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors for individual patient antibiotic treatment effect in hospitalized community-acquired pneumonia patients.
    Simonetti AF; van Werkhoven CH; Schweitzer VA; Viasus D; Carratalà J; Postma DF; Oosterheert JJ; Bonten MJM
    Clin Microbiol Infect; 2017 Oct; 23(10):774.e1-774.e7. PubMed ID: 28336384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penicillin treatment for patients with Community-Acquired Pneumonia in Denmark: a retrospective cohort study.
    Egelund GB; Jensen AV; Andersen SB; Petersen PT; Lindhardt BØ; von Plessen C; Rohde G; Ravn P
    BMC Pulm Med; 2017 Apr; 17(1):66. PubMed ID: 28427381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
    Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
    Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study.
    Siegel RE; Alicea M; Lee A; Blaiklock R
    Am J Ther; 1999 Jul; 6(4):217-22. PubMed ID: 11329100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.